One Year Survival of Extrahepatic Cholangiocarcinoma Patients Who Did Not Undergo Curative Resection and Paliative Chemotherapy and Its Associated Factors

Pieter Saragih, Dadang Makmun, Juferdy Kurniawan, Ikhwan Rinaldi


Background: Extrahepatic cholangiocarcinoma is rare but fatal. Patients who come are usually already in the advanced stage that can not undergo curative resection and chemotherapy also seems to be very rarely done. The survival rate and its associated factors in Indonesia are unknown. This study aimed to identify 1-year survival of patients with extrahepatic cholangiocarcinoma without curative resection and palliative chemotherapy and its associated factors. Methods: This is a cross-sectional study using medical records of extrahepatic cholangiocarcinoma (perihilar and distal) inpatient and outpatient patients at Cipto Mangunkusumo Hospital, Jakarta from January 2015 to March 2020, reviewed retrospectively. The following factors were analyzed in terms of mortality: metastasis, sepsis, hypoalbuminemia, serum bilirubin level, serum CA 19-9 level, billiary drainage, neutrophyl lympocyte ratio (NLR) and comorbid factors. Results: 115 out of 144 patients were enrolled in this study with male proportion of 50.4%, and proportion of patients aged 65 years or above was 71.3%. 1 year survival rate was 10 % and median survival was 3 months (CI 95% 2.388-3.612)Multivariate analysis showed that only sepsis, unsuccessful or no prior biliary drainage and total bilirubin >19.8 mg/dl were independent predictors of mortality. Conclusion: 1 year survival of extrahepatic cholangiocarcinoma without curative resection and paliative chemotherapy was 10 %.Sepsis, unsuccessful or no prior bilirary drainage, and total biirubin >19.8 mg/dl  are factors significantly associated with shortened survival in malignant obstructive jaundice patients.


survival; extrahepatic cholangiocarcinoma; curative resection; paliative chemotherapy; mortality-related factors


Patel T. Cholangiocarcinoma: controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200.

Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: A large-scale observational study. Gut Liver. 2009;3(4):298-305.

Kurniawan J HI, Gani RA, Simadibrata M. Mortality-related factors in patients with malignant obstructive jaundice. Acta Med Indones. 2016;48(4):282-7.

Fernandez-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol. 2009;15(42):5279-86.

Aktas G KT, Balkan A, Metin T, Gulsen MT, Abali H. Prognostic factors in patients with advanced extrahepatic cholangiocarcinoma. Medicine (Baltimore). 2019;98:e14556.

Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O. Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(10):2097-100.

Wu CE, Chou WC, Hsieh CH, et al. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience. BMC Cancer. 2020;20(1):422.

Wang Y, Pang Q, Jin H, et al. Albumin-bilirubin grade as a novel predictor of survival in advanced extrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2018:8902146.

Khan SA DB, Goldin RD, Heaton N, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657-69.

Yusoff AR, Razak MM, Yoong BK, Vijeyasingam R, Siti ZM. Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. World J Gastroenterol. 2012;18(5):458-65.

Benavides MAA, J Gallego, Go´mez MA, et al. Biliary tract cancers: SEOM guidelines. Clin Trans Oncol. 2015;17:982-7.

Weber A LS, Scnhneider J, Stangl M, et al. Long term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol. 2007;13(9):1422-6.

Yang LC SH, Huang JW, Lee KT. Biliary stenting for unresectable cholangiocarcinoma: A population based study of long term outcomes and hospital costs in Taiwan. Kaohsiung J Med Sci. 2015;31(7):370-6.

Qiu YD BJ, Xu FG, Ding YT. Effect of perioperative biliary drainage on malignant obstructive jaundice : a metaanalysis. World J Gastroenterol. 2011;17(3):391-6.

Pavlidis ET PT. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int. 2018;17(1):17-21.

Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc. 2002;56(6):885-9.

Li L, Zhu C, Huang H. Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae. Ann Transl Med. 2019;7(14):304.

Gaspersz MP, Buettner S, van Vugt JLA, et al. Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford). 2017;19(11):966-71.

Zhang GY, Li WT, Peng WJ, Li GD, He XH, Xu LC. Clinical outcomes and prediction of survival following percutaneous biliary drainage for malignant obstructive jaundice. Oncol Lett. 2014;7(4):1185-90.

Brountzos EN, Ptochis N, Panagiotou I, Malagari K, Tzavara C, Kelekis D. A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting. Cardiovasc Intervent Radiol. 2007;30(1):66-73.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.